Yidan Zhang

General Manager, Head of Clinical Development, CN

In July 2023, Yidan Zhang joined ReLive Biotechnologies as Senior Director of Clinical Development.

Yidan has more than 12 years of experience and profound expertise in translational medicine, clinical development, and regulatory affairs of novel drugs. He is a well-trained Surgeon specializing in spinopelvic surgeries, multidisciplinary treatment of sarcomas/metastatic tumors, prosthetic/biologic reconstructions, and tissue regeneration.

Previously, Yidan worked as a Surgeon-Scientist at the department of Musculoskeletal Tumor Center, Peking University People's Hospital (PKUPH), China. Next to his work as a Surgeon, he served as Principal Investigator of three studies in novel drug development, therapeutic targets, and application of artificial intelligence in radiographic diagnose. As a post-doc fellow at the Albert Einstein College of Medicine (AECM) in New York, US, his focus was on stem cells and bone cancer. In 2020, he entered the industry as Vice President at Angitia Biotechnologies Ltd, where he was responsible for clinical development, clinical operation, pharmacovigilance, and regulatory affairs. In his position, he made significant contributions to the progress of clinical studies as well as the grant of orphan drug and rare pediatric disease designation. Moreover, he is the author or co-author of several scientific publications.

Yidan holds a Doctor of Medicine (MD) from the Peking Union Medical College (eight-year program), Beijing, China. He obtained an MBA from the School of Economic Management at Tsinghua University, Beijing, China.